Cited by 649Lipoproteins and Cardiovascular HealthChronic Kidney Disease and DiabetesDialysis and Renal Disease Management

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient

Wanner, Christoph, the Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members, Tonelli, Marcello·2014·Kidney International

DOI 10.1038/ki.2014.31

Open this paper in CoChat — free account

Abstract

The Kidney Disease: Improving Global Outcomes (KDIGO) organization developed clinical practice guidelines on lipid management for all adults and children with chronic kidney disease (CKD). Thirteen recommendations were obtained from the available evidence outlining a three-step management including assessment in all, treatment in many, and follow-up measurements in few. A key element is the recommendation of statin or statin/ezetimibe treatment in adults aged ⩾50 years with estimated glomerular filtration rate (eGFR) <60 ml/min per 1.73 m(2) but not treated with chronic dialysis or kidney transplantation. In dialysis patients, the magnitude of any relative reduction in risk appears to be substantially smaller than in earlier stages of CKD and initiation of statin treatment is not recommended for most prevalent hemodialysis patients. In the past, clinical practice guidelines suggested the use of targets for LDL cholesterol, which require repeated measurements. Treatment escalation with higher doses of statin would be a consequence when LDL cholesterol targets are not met. The KDIGO Work Group did not recommend this strategy because higher doses of statins have not been proven to be safe in the setting of CKD. Since LDL cholesterol levels do not necessarily suggest the need to increase statin doses, follow-up measurement of lipid levels is not recommended.

Integrity signals

Registry

Crossref · 10.1038/ki.2014.31

Cites

0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
Fellström, B. C., Jardine, A. G., Schmieder, R. E., Holdaas, H., Bannister, K., Beutler, J., Chae, D.-W., Chevaile, A., Cobbe, S. M., Grönhagen-Riska, C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810177 · Cited by 2,036
Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
Jun, M., Foote, C., Lv, J., Neal, B., Patel, A., Nicholls, S. J., Grobbee, D. E., Cass, A., Chalmers, J., & Perkovic, V. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60656-3 · Cited by 927
Effects of Atorvastatin on Kidney Outcomes and Cardiovascular Disease in Patients With Diabetes: An Analysis From the Collaborative Atorvastatin Diabetes Study (CARDS)
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., Neil, H. A. W., Livingstone, S. J., Charlton-Menys, V., DeMicco, D. A., & Fuller, J. H. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.03.022 · Cited by 255
National Cholesterol Education Program recommendations for measurement of high-density lipoprotein cholesterol: executive summary. The National Cholesterol Education Program Working Group on Lipoprotein Measurement
Warnick, G. R., & Wood, P. D. (1995) · Clinical Chemistry · doi:10.1093/clinchem/41.10.1427 · Cited by 212

Flagged first, then by citations

Show all 0 references

Research works printed but not linked: 38

Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group, 2013, KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease, Kidney Int Suppl, 3, 259
Uhlig, 2006, Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO), Kidney Int, 70, 2058, 10.1038/sj.ki.5001875 · DOI
National Kidney Foundation, 2003, K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease, Am J Kidney Dis, 41, S1
Grundy, 2006, Diabetes and coronary risk equivalency: what does it mean?, Diabetes Care, 29, 457, 10.2337/diacare.29.02.06.dc05-1904 · DOI
Lewington, 2007, Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths, Lancet, 370, 1829, 10.1016/S0140-6736(07)61778-4 · DOI · Paper page
Chiang, 2005, Low-density lipoprotein cholesterol: association with mortality and hospitalization in hemodialysis patients, Blood Purif, 23, 134, 10.1159/000083529 · DOI
Coresh, 1998, Epidemiology of cardiovascular risk factors in chronic renal disease, J Am Soc Nephrol, 9, S24
Iseki, 2002, Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients, Kidney Int, 61, 1887, 10.1046/j.1523-1755.2002.00324.x · DOI
Lowrie, 1990, Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities, Am J Kidney Dis, 15, 458, 10.1016/S0272-6386(12)70364-5 · DOI
Krane, 2009, Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus, Am J Kidney Dis, 54, 902, 10.1053/j.ajkd.2009.06.029 · DOI
Liu, 2004, Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition, J Am Med Assoc, 291, 451, 10.1001/jama.291.4.451 · DOI
Tonelli, 2013, Association between LDL-C and risk of myocardial infarction in CKD, J Am Soc Nephrol, 24, 979, 10.1681/ASN.2012080870 · DOI
Kasiske, 1998, Hyperlipidemia in patients with chronic renal disease, Am J Kidney Dis, 32, S142, 10.1053/ajkd.1998.v32.pm9820472 · DOI
Bachorik, 1995, National Cholesterol Education Program recommendations for measurement of low-density lipoprotein cholesterol: executive summary. The National Cholesterol Education Program Working Group on Lipoprotein Measurement, Clin Chem, 41, 1414, 10.1093/clinchem/41.10.1414 · DOI
Stein, 1995, National Cholesterol Education Program recommendations for triglyceride measurement: executive summary. The National Cholesterol Education Program Working Group on Lipoprotein Measurement, Clin Chem, 41, 1421, 10.1093/clinchem/41.10.1421 · DOI
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, 2001, Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III), J Am Med Assoc, 285, 2486, 10.1001/jama.285.19.2486 · DOI · Paper page
Kilpatrick, 2007, Association between serum lipids and survival in hemodialysis patients and impact of race, J Am Soc Nephrol, 18, 293, 10.1681/ASN.2006070795 · DOI
Glasziou, 2008, Monitoring cholesterol levels: measurement error or true change?, Ann Intern Med, 148, 656, 10.7326/0003-4819-148-9-200805060-00005 · DOI
Takahashi, 2010, Lipid re-screening: what is the best measure and interval?, Heart, 96, 448, 10.1136/hrt.2009.172619 · DOI
Baigent, 2011, The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial, Lancet, 377, 2181, 10.1016/S0140-6736(11)60739-3 · DOI · Paper page
Palmer, 2012, Benefits and harms of statin therapy for persons With chronic kidney disease: a systematic review and meta-analysis, Ann Intern Med, 157, 263, 10.7326/0003-4819-157-4-201208210-00007 · DOI · Paper page
Tonelli, 2006, Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial, BMJ, 332, 1426, 10.1136/bmj.38814.566019.2F · DOI
Wanner, 2005, Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis, N Engl J Med, 353, 238, 10.1056/NEJMoa043545 · DOI · Paper page
Marz, 2011, Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis, Clin J Am Soc Nephrol, 6, 1316, 10.2215/CJN.09121010 · DOI
Holdaas, 2003, Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial, Lancet, 361, 2024, 10.1016/S0140-6736(03)13638-0 · DOI · Paper page
Saland, 2002, Dyslipidemia in pediatric renal disease: epidemiology, pathophysiology, and management, Curr Opin Pediatr, 14, 197, 10.1097/00008480-200204000-00009 · DOI
Saland, 2007, Lipoprotein metabolism in chronic renal insufficiency, Pediatr Nephrol, 22, 1095, 10.1007/s00467-007-0467-5 · DOI
Strong, 1999, Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study, JAMA, 281, 727, 10.1001/jama.281.8.727 · DOI
National Kidney Foundation, 2009, KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 update, Am J Kidney Dis, 53, S1, 10.1053/j.ajkd.2008.11.017 · DOI
Coleman, 1996, Hyperlipidaemia, diet and simvastatin therapy in steroid-resistant nephrotic syndrome of childhood, Pediatr Nephrol, 10, 171, 10.1007/BF00862065 · DOI
Garcia-de-la-Puente, 2009, Efficacy of simvastatin in children with hyperlipidemia secondary to kidney disorders, Pediatr Nephrol, 24, 1205, 10.1007/s00467-009-1128-7 · DOI
Sanjad, 1997, Management of hyperlipidemia in children with refractory nephrotic syndrome: the effect of statin therapy, J Pediatr, 130, 470, 10.1016/S0022-3476(97)70213-0 · DOI
Yoshimura, 1992, The effects of pravastatin on hyperlipidemia in renal transplant recipients, Transplantation, 53, 94, 10.1097/00007890-199201000-00018 · DOI
Zhao, 2012, New fibrate use and acute renal outcomes in elderly adults a population-based study, Ann Intern Med, 156, 560, 10.7326/0003-4819-156-8-201204170-00401 · DOI · Paper page
Cerkauskiene, 2003, Influence of omega-3 fatty acids on lipid metabolism in children with steroid sensitive nephritic syndrome], Medicina, 39, 82
Chongviriyaphan, 1999, Effects of tuna fish oil on hyperlipidemia and proteinuria in childhood nephritic syndrome, J Med Assoc Thai, 82, S122
Goren, 1991, Fish oil treatment of hyperlipidemia in children and adolescents receiving renal replacement therapy, Pediatrics, 88, 265, 10.1542/peds.88.2.265 · DOI
Hogg, 2006, Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group, Clin J Am Soc Nephrol, 1, 467, 10.2215/CJN.01020905 · DOI

Sorted by citations

Items 401–500 of 570

Renal Medicine and Clinical Pharmacy
Braund, R. (2020) · Advanced Clinical Pharmacy - Research, Development and Practical Applications · doi:10.1007/978-3-030-37655-0 · Cited by 3
“The fractional excretion of sodium in the urine is increased by the remaining func- Adapted from the KDIGO Clinical Practice Guideline for Lipid Management in CKD 2013 (Wanner and Tonelli 2014) Dose based on 14D, 2ALERT, 3AURORA, 4SHARP.”
Method
Nutrition Therapy in Critically Ill Overweight Elderly Patient with Heart Failure, Myocardial Infarction, Pneumonia, and Chronic Kidney Disease
Rusli, C., Bukhari, A., Taslim, N. A., As’ád, S., & Rasyid, H. (2020) · Journal of Nutritional Science and Vitaminology · doi:10.3177/jnsv.66.s25 · Cited by 4
Considerations in Applying the Results of Randomized Controlled Clinical Trials to the Care of Older Adults With Kidney Disease in the Clinical Setting: The SHARP Trial
Butler, C. R., & O’Hare, A. M. (2015) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2015.11.004 · Cited by 2
Narrative review on decoding the crosstalk between lipid homeostasis and immune pathways in membranous nephropathy
Ma, S., Chang, M., Chen, S., Han, T., Zhang, S., Wang, H., & Feng, G. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04713-z · Cited by 2
Predictors of Escalation of Lipid-Lowering Therapy with Subanalysis of the Influence of Lipoprotein (a) on the Decision-Making Process
Muszyński, P., Dudzińska, K., Święcicka, M., Grądzka-Matys, W., Kazberuk, M., Musiałowska, D., Kruszyńska, J., Kazberuk, P., Bajda, U., & Tomaszuk−Kazberuk, A. (2025) · Diseases · doi:10.3390/diseases14010008 · Cited by 2
Empfehlungen zur Diagnostik und Therapie der chronischen Nierenkrankheit (CKD) der Österreichischen Gesellschaft für Nephrologie
Ksiazek, S. H., Windpessl, M., Zitt, E., Rudnicki, M., Eller, K., Schwarz, C., Antlanger, M., Schmaldienst, S., Cejka, D., Oberbauer, R. W., et al. (2025) · Wiener klinische Wochenschrift · doi:10.1007/s00508-025-02590-y · Cited by 3
Differences in chronic kidney disease management based on identification and diagnosis in a population-based observational study
Olszewski, M., Bjurström, K., Lingman, M., Henrohn, D., Shojaiyan, P., Garell, M., & Agvall, B. (2025) · Journal of Nephrology · doi:10.1007/s40620-025-02414-2 · Cited by 1
Management of Dyslipidemia in Chronic Kidney Disease
Vedamurthy, D., Sagheer, U., Patel, A., Singh, G., & Kalra, D. K. (2025) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-025-00763-y · Cited by 2
“Statins and ezetimibe are recommended to be initiated in all patients except ESRD patients on dialysis unless it is used for secondary prevention of ASCVD [28].”
Influential
Cardiac evaluation in patients awaiting kidney transplant-position statement of the Cardiological Society of India and Indian Society of Nephrology
Bahl, A., Prasad, N., Sinha, D. P., Ganguly, K., Roy, S., Roy, D., Rakshit, S., Kumar, D. L., Das, S., Bhasin, D., et al. (2025) · Indian Heart Journal · doi:10.1016/j.ihj.2025.03.012 · Cited by 2
Managing Dyslipidemia in Children: Current Approaches and the Potential of Artificial Intelligence.
Zaheer, A., Saeed, H., Arshad, M. K., Iftikhar, U., Abid, A., Khan, M. H., Khan, A., & Akbar, A. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000816 · Cited by 2
Circulating osteoprotegerin and progression of coronary artery calcification in patients with chronic kidney disease: the KoreaN Cohort Study for Outcome in Patients With Chronic Kidney Disease (KNOW-CKD)
Suh, S.-H.-O., Oh, T. R., Choi, H.-S., Kim, C., Bae, E., Ma, S., Oh, K.-H., Yoo, T.-H., & Kim, S. (2024) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.24.039 · Cited by 2
“Indeed, guidelines on the management of cardiovascular complications in CKD emphasize the prevention of CAD [5–7].”
Approach to Late Noninfectious Post-Transplant Complications
Alasfar, S., Me, H. M., & Budhiraja, P. (2024) · Advances in Kidney Disease and Health · doi:10.1053/j.akdh.2024.05.005 · Cited by 2
Effect of Lipid‐Lowering Drugs on Renal and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Dyslipidemia: A Retrospective Cohort Study
Lin, Y.-C., Tsao, H.-M., Lai, T.-S., Chen, Y.-T., Chou, Y.-H., Lin, S.-L., Chen, Y.-M., Hung, K.-Y., & Tu, Y.-X. (2023) · Clinical pharmacology and therapy · doi:10.1002/cpt.3060 · Cited by 2
“14 The Research Ethics Committee approved the study at the National Taiwan University Hospital and waived the need for participant consent.”
BackgroundMethod
Management of Hypertension and Associated Cardiovascular Disease in Autosomal Dominant Polycystic Kidney Disease
Rahbari-Oskoui, F. F. (2023) · Advances in Kidney Disease and Health · doi:10.1053/j.akdh.2023.03.004 · Cited by 2
Association of statin use after renal replacement therapy with mortality in patients with dialysis-requiring acute kidney injury
Chang, H.-H., Liu, W.-C., & Tsai, T. (2023) · International Urology and Nephrology · doi:10.1007/s11255-023-03681-3 · Cited by 2
“To reduce cardiac death in patients with CKD, the Kidney Disease Improving Global Outcomes guideline recommends that all patients aged ≥ 50 years with any CKD stages and even young patients with CKD possessing risk factors of cardiovascular disease (CVD) should receive statin therapy [30].”
Chronic kidney disease as a risk factor for acute stroke
Rzhevskaya, O. N., Moiseeva, A., Esaulenko, A. N., Pinchuk, A., & Alidzhanova, K. (2021) · Transplantologiya. The Russian Journal of Transplantation · doi:10.23873/2074-0506-2021-13-4-382-397 · Cited by 2
Mild Malnutrition Contributes the Greatest to the Poor Prognosis in Coronary Artery Disease With Well-Controlled Low-Density Lipoprotein Cholesterol Levels: A 4,863 Chinese Cohort Study
Wang, B., Guo, Z.-D., Liu, J., Li, H.-Q., Mai, Z.-L., Lin, F., Ying, M., Yu, Y., Chen, S., Li, Q., et al. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.725537 · Cited by 2
“Various studies suggest that there are significant opportunities to improve treatment of identified risk factors, and KDIGO guidelines for lipid management in CKD provide specific treatment recommendations (42).”
Background
Approach to stable angina in patients with advanced chronic kidney disease
Arif, H., & Yadav, A. (2021) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000709 · Cited by 2
“In the wake of the 4D [56], AROURA [57] and the SHARP trials [58], the recommendations by KDIGO are to treat hyperlipidaemia in patients with CKD, not on dialysis aged at least 50 years with either statins or statin and ezetimibe [59].”
Method
Risk Factors and Management of Kidney Diseases in Saudi Women with Diabetes
Siddiqui, K., & Joy, S. S. (2020) · Current Women s Health Reviews · doi:10.2174/1573404816666200206110002 · Cited by 2
El continuo cardiorrenal: una propuesta para la prevención de las enfermedades cardiovasculares y renales
Pablo Amair, M., & Arocha-Rodulfo, I. (2020) · Revista Colombiana de Nefrología · doi:10.22265/acnef.7.1.356 · Cited by 2
Not even a peripheral role for statins in end-stage renal disease?
Lee, K., Chan, G., & Tang, S. (2020) · Nephrology, Dialysis and Transplantation · doi:10.1093/ndt/gfaa051 · Cited by 2
Langzeitkomplikationen nach viszeraler Organtransplantation
Darstein, F., Zimmermann, T., & Lang, H. (2019) · Der Gastroenterologe · doi:10.1007/s11377-019-0360-3 · Cited by 2
Diabetische Nierenerkrankung (Update 2019)
Sourij, H., Edlinger, R., Prischl, F. C., Auinger, M., Kaser, S., Horn, S., Paulweber, B., Kautzky‐Willer, A., Säemann, M. D., Prager, R., et al. (2019) · Wiener klinische Wochenschrift · doi:10.1007/s00508-018-1425-x · Cited by 3
Current guidelines in peritoneal dialysis – Part I
Ferreira, A., Borges, A., Abreu, C., Costa, F., Pereira, M., Castro, R., & Barreto, S. (2019) · Portuguese Journal of Nephrology and Hypertension · doi:10.32932/pjnh.2019.04.007 · Cited by 2
Modifying Effect of Statins on Fatal Outcomes in Chronic Kidney Disease Patients in the Systolic Blood Pressure Intervention Trial: A Post Hoc Analysis
Rivera, M., Tamariz, L., Suarez, M. M., & Contreras, G. (2019) · American Journal of Nephrology · doi:10.1159/000499188 · Cited by 2
Does an Apple (or Many) Each Day, Keep Mortality Away?
Moorthi, R. (2019) · American Society of Nephrology. Clinical Journal · doi:10.2215/cjn.15001218 · Cited by 2
“The 2013 Lipid Guidelines discuss dietary changes to reduce serum triglycerides,with thecaveat that it is aweakrecommendation,made on the basis of very low-quality evidence (9).”
Background
Lipid lowering in dialysis patients with cardiovascular disease who are awaiting kidney transplantation
Aziz, F., Garg, N., Parajuli, S., Djamali, A., Stein, J., & Mandelbrot, D. (2018) · Clinical Transplantation · doi:10.1111/ctr.13452 · Cited by 2
Therapeutic Management of Dyslipidemia Patients at Very High Cardiovascular Risk (CARDIO TRACK): Protocol for the Observational Registry Study
Naidoo, P., Mothilal, R., & Blom, D. (2018) · JMIR Research Protocols · doi:10.2196/resprot.9248 · Cited by 2
“Severe renal impairment alters the pharmacokinetics of statins by reducing renal elimination and requires dose reduction to limit deleterious effects including myositis and rhabdomyolysis [12,13].”
Diabetes mellitus and cardiovascular risk: Update of the recommendations of the Diabetes and Cardiovascular Disease working group of the Spanish Diabetes Society (SED, 2018)
Arrieta, F., Iglesias, P., Pedro‐Botet, J., Becerra, A., Ortega, E., Obaya, J. C., Nubiola, A., Maldonado, G. F., Campos, M. D. M., Petrecca, R., et al. (2018) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2018.05.002 · Cited by 10
Estatinas en enfermedad renal crónica
Palamara, R. S., Milad, R. J., Llona, A. A. A., Alberto Maiz, G., & R, A. R. (2017) · doi:10.11565/arsmed.v42i1.654 · Cited by 2
“Por otro lado, pacientes que ya eran usuarios de estatinas pueden continuarla cuando entran a diálisis (Wanner & Tonelli, 2014).”
BackgroundInfluential
Left ventricular mass and cardiac function in pediatric dialysis patients
Rinat, C., Nir, A., & Frishberg, Y. (2016) · doi:10.1016/j.ppedcard.2015.11.002 · Cited by 2
The Role of the Chronic Kidney Disease Clinic and Multidisciplinary Team Care
Nataatmadja, M., Graham, J. M., Beaulieu, M., Zalunardo, N., & Levin, A. (2019) · Chronic Kidney Disease, Dialysis, and Transplantation · doi:10.1016/b978-0-323-52978-5.00008-2 · Cited by 2
Chapter 56 – Management of Dyslipidemia in Long-Term Dialysis Patients
Palmer, S., & Strippoli, G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-39154-2.00056-4 · Cited by 2
Nudging Nephrologists in Cardiovascular Risk Assessment and Management in Glomerular Diseases Treated with Immunosuppressants: An Implementation Study
Sim, J., Loo, F., Lim, L., Chia, S., Lek, R., Tan, H. Z., Mok, I., Lee, T.-L., Choo, J., Tan, C.-S.-A., et al. (2026) · Glomerular Diseases · doi:10.1159/000551591 · Cited by 1
“Many of the current guidelines for lipid management in glomerulonephritis and CKD do not have explicit targets of absolute biochemical values [44, 45], while treatment strategies (e.g., “intensive” therapy) may depend on the individualized cardiovascular risk assessment [14].”
Ten-Year Clinical Outcomes and Cause of Death in Patients on Dialysis Undergoing Percutaneous Coronary Intervention: A Retrospective Mayo Clinic PCI Registry Analysis
Nagaraja, V., Lewis, B. R., Korsapati, H., Mene-Afejuku, T. O., Dillon, J. J., Cheungpasitporn, W., Gharacholou, M., Reeder, G. S., Hibbert, B. M., Best, P. J. M., et al. (2026) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2025.11.016 · Cited by 1
Clinical Profile and Outcomes of Patients with Chronic Kidney Disease on Chronic Hemodialysis Hospitalized for Acute Coronary Syndrome in a Tertiary Public Hospital in the Philippines
Mapili, J., Tuazon, C. A., Alad, P. A., Pilapil, J. C., Velando, B., Bondoc, A., Lim, L. C., Cabujat-Bumanglag, M. A. K., Tang, V., Lao, J., et al. (2026) · Acta medica Philippina · doi:10.47895/amp.vi0.12145 · Cited by 1
“10,11 Currently, there is paucity of data regarding the clinical profile and its association to clinical outcomes among patients who are on chronic hemodialysis and are hospitalized for ACS.”
Peroxisome proliferator-activated receptors in kidney diseases: A promising therapeutic target.
Li, Q.-Y., Shi, Z.-W., Shi, X.-J., Xing, H., Zhang, Y., Zhuang, S., & Chang, M.-Y. (2026) · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · doi:10.1016/j.biopha.2026.118983 · Cited by 1
A Pilot Study of Opportunistic Chronic Kidney Disease Screening in Primary Care Using a Clinical Decision Support System
López-Garrigós, M., Puig, E., Sánchez, S., Gutierrez, I., Salinas, M., Ortiz, A., & Flores, E. (2025) · Diagnostics · doi:10.3390/diagnostics16010008 · Cited by 1
“By applying guidelines in real-time, the CDSS ensures that interventions are both timely and appropriate, leading to better patient outcomes [7,8,18,19].”
Biomarker-based depression risk prediction in chronic heart failure patients: an interpretable machine learning approach
Tao, Y., Yao, C.-L., Liu, R., Qiu, H., Liu, X., Wang, B., & Li, H. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1737713 · Cited by 1
Kidney transplantation and statins effects on dyslipidemia in kidney transplant recipients
Arabi, Z., Tawhari, M. H., Arabi, T., Alaklabi, A., Fallatah, W., Sabbah, B., AlGhamdi, A. A. A., Alnasrullah, A., & Shafqat, A. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000003903 · Cited by 1
“However, the effect of KTx cannot be ethically assessed without the use of statins since the use of statins in this high-risk group is considered standard of care [ 13 ] .”
Influential
Statin use and acute kidney injury among hospitalized chronic kidney disease patients: a retrospective cohort study
Tang, L., Xu, D., Xu, L., Zhao, Y., Zhu, Y.-D., Lv, J., Yang, L., & Zheng, X. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1639130 · Cited by 2
Retrospective analysis of statin use and arteriovenous fistula thrombosis in hemodialysis: Is there a dose-dependent effect?
Stepanova, N., Ostapenko, T., Marchenko, V., Holovanova, A., Lysii, M., Kucher, T., Filonov, V., Dzhur, V., Stetsenko, B., Moroid, H., et al. (2025) · Ukrainian Journal of Nephrology and Dialysis · doi:10.31450/ukrjnd.2(86).2025.03 · Cited by 1
Lipid and immunophenotypic profiles in hemodialysis patients with citrate vs. acetate dialysates
Rodríguez-Espinosa, D., Cuadrado-Payán, E., Morantes, L., Gómez, M., Maduell, F., & Broseta, J. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1497353 · Cited by 1
Prescribing patterns in older people with advanced chronic kidney disease towards the end of life
Letts, M., Chesnaye, N. C., Pippias, M., Caskey, F. J., Jager, K. J., Dekker, F. W., van Diepen, M., Evans, M., Torino, C., Vilasi, A. D., et al. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae301 · Cited by 2
Self-citation
Proprotein convertase subtilisin/kexin type 9 (PCSK9) and clinical outcomes in dialysis patients
Torino, C., Carbone, F., Pizzini, P., Mezzatesta, S., D'Arrigo, G., Gori, M., Liberale, L., Moriero, M., Michelauz, C., Frè, F., et al. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14235 · Cited by 1
The Impact of an Educational Intervention on Enhancing Clinical Knowledge of Physicians and Pharmacists Regarding Statins and Monitoring Parameters: The Experience of a Tertiary Teaching Hospital
Al-Ashwal, F. Y., Sulaiman, S. A. S., Ghadzi, S. M. S., Harun, S. N., Halboup, A. M., & Kubas, M. A. (2024) · Advances in Medical Education and Practice · doi:10.2147/amep.s445610 · Cited by 5
“26,27 28 However, some statins need dosage adjustments based on creatinine clearance.”
Background
Stroke and kidney transplantation
Abreo, A. P., Kataria, D., Amrutkar, C. V., Singh, A., Samaniego, M., & Singh, N. K. (2023) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000001078 · Cited by 1
“However, follow-up is recommended in a select group of patients (Table 2) [54].”
Background
Transcriptomic analysis identifies novel candidates in cardiorenal pathology mediated by chronic peritoneal dialysis
Nasci, V. L., Liu, P.-Y., Marks, A. M., Williams, A. C., & Kriegel, A. J. (2023) · Scientific Reports · doi:10.1038/s41598-023-36647-7 · Cited by 1
“Current lipid treatment recommendations from KDIGO for PD patients suggest that statin treatments are not effective at reducing CV risk and while triglyceride targeting medications like fibrates can reduce risk the increase in plasma creatinine contraindicates them for use in this population 17 .”
Diabetische Nierenerkrankung (Update 2023)
Sourij, H., Edlinger, R., Prischl, F. C., Kaser, S., Horn, S., Antlanger, M., Paulweber, B., Aberer, F., Brix, J. M., Cejka, D., et al. (2023) · Wiener klinische Wochenschrift · doi:10.1007/s00508-022-02147-3 · Cited by 1
Cardiovascular Risk Stratification and Appropriate Use of Statins in Patients with Chronic Kidney Disease According to Different Strategies
Barbagelata, L., Masson, W., Rossi, E., Lee, M., Lagoria, J., Vilas, M., Pizarro, R., & Díez, G. R. R. (2022) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-022-00531-8 · Cited by 1
“Applying recommendations of the 2013 KDIGO guidelines [10], the following patients should be considered for receiving statins: (a) patients > 50 years with CKD (grades 3–5, without dialysis), regardless of LDL-C levels; (b) patients < 50 years with CKD (grades 3–5, without dialysis), with cardiovascular disease histor…”
BackgroundMethod
Kidney Function and Lipid Levels in Older Adults: The Atherosclerosis Risk in Communities Study
Srivastava, S., Coresh, J., Rebholz, C., Grams, M., Matsushita, K., Martin, S., & Shin, J.-I. (2022) · Kidney Medicine · doi:10.1016/j.xkme.2022.100494 · Cited by 1
“In addition to LDL-C levels, attention to the burden of high TG and low HDL-C levels may be needed to improve clinical outcomes in older adults with CKD. Kidney Med Vol 4 | Iss 7 | July 2022 | 100494 Shreya Srivastava, MD, MPH, Josef Coresh, MD, PhD, Casey M. Rebholz, PhD, MS, MNSP, MPH, Morgan E. Grams, MD, PhD, Kuni…”
BackgroundInfluential
Managing the Nutritional Requirements of the Pediatric End-Stage Kidney Disease Graduate.
Nelms, C., Shroff, R., Boyer, O., & Topaloğlu, R. (2022) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2022.04.004 · Cited by 1
Screening for Cardiovascular Disease in CKD: COMMENTARY.
McCallum, W., & Sarnak, M. (2022) · Kidney360 · doi:10.34067/kid.0000742022 · Cited by 1
“We agree with the general concept of risk assessment in patients with CKD, and support the KDIGO lipid guidelines which state that the vast majority of patients with CKD and above the age of 50 years are at high risk for CAD and should take statins.(3) We also agree with tight BP control, healthy diet, and improved gl…”
Result
Diabetes mellitus and cardiovascular risk: an update of the recommendations of the Diabetes and Cardiovascular Disease Working Group of the Spanish Society of Diabetes (SED, 2021)
Arrieta, F., Pedro‐Botet, J., Iglesias, P., Obaya, J. C., Montánez, L., Maldonado, G. F., Becerra, A., Navarro, J., Perez, J. C., Petrecca, R., et al. (2022) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2022.01.005 · Cited by 1
Pleiotropic effects of atorvastatin in peritoneal dialysis patients: A retrospective-prospective observational cohort study
Burdeyna, O. (2022) · Ukrainian Journal of Nephrology and Dialysis · doi:10.31450/ukrjnd.1(73).2022.08 · Cited by 1
Effect of pravastatin on erythrocyte membrane fatty acid contents in patients with chronic kidney disease
Lee, S. M., Son, Y. K., Kim, S. E., Kim, Y. H., Park, Y., & An, W. S. (2021) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.20.247 · Cited by 1
Advanced kidney disease: What the nonnephrology NP needs to know.
Puzantian, H., & Mead, D. R. (2020) · The Nurse Practitioner · doi:10.1097/01.npr.0000722304.42807.02 · Cited by 1
“In cardiovascular disease prevention, low to moderate doses of statins can be used in patients with CKD starting at 50 years of age.(13,27) Statin initiation is not recommended for patients on kidney replacement therapies as there is no clear evidence of cardiovascular or survival benefi t.”
Background
Effect of atorvastatin on inflammatory markers in hemodialysis patients
Hussein, H., Mady, G., Shawky, S., Omran, N. A., & Teama, N. (2020) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-020-00007-y · Cited by 1
Supporting physicians in the management of metabolic alterations in adult kidney transplant recipients: a comment on the joint position statement of the Italian Society of Nephrology (SIN), the Italian Society for Organ Transplantation (SITO) and the Italian Diabetes Society (SID)
Conte, C., Maggiore, U., Cappelli, G., Ietto, G., Lai, Q., Salis, P., Marchetti, P., Piemonti, L., Secchi, A., Capocasale, E., et al. (2020) · JN. Journal of Nephrology (Milano. 1992) · doi:10.1007/s40620-020-00839-5 · Cited by 1
Associations of Waist Circumference, Socioeconomic, Environmental, and Behavioral Factors with Chronic Kidney Disease in Normal Weight, Overweight, and Obese People
Duong, T. V., Wu, P.-Y., Yang, E., Lin, Y.-F., Chiou, H., & Yang, S.-H. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16245093 · Cited by 1
Links lipoproteins to chronic kidney disease and atherosclerosis
Lu, H. S., Kukida, M., & Daugherty, A. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000625 · Cited by 1
Association between individual cholesterol and proteinuria response and exposure to atorvastatin or rosuvastatin
Kroonen, M., Stevens, J., de Zeeuw, D., & Heerspink, H. (2019) · Diabetes, obesity and metabolism · doi:10.1111/dom.13849 · Cited by 1
“Lipid-lowering therapy is part of the guideline recommended treatment for cardiovascular protection in patients with diabetes and chronic kidney disease.(1) The effects of statins on kidney function remain unclear.”
Background
Statins and Mortality in Connective Tissue Diseases: Should We Resume the Cardio-rheumatology Spirit in Our Clinics?
Gremese, E., Lorenzis, E. D., & Ferraccioli, G. (2018) · Journal of Rheumatology · doi:10.3899/jrheum.180732 · Cited by 1
Statins at Dialysis Transition-Supportive but Not Sufficient.
Edmonston, D., Wolf, M., & Pencina, M. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.2411 · Cited by 1
Dyslipidemias in CKD and ESKD: Outcomes and Management
Carruthers, D., & Rohatgi, A. (2017) · Springer eBooks · doi:10.1007/978-3-319-56042-7_35 · Cited by 1
Acute Renal Failure in the Elderly, over the Age of 75, in the Medical and Rehabilitation Hospital of Saint-Maurice (Paris - France)
Bah, A., Bah, M. L., Péquignot, R., & Kimso, O. (2015) · doi:10.4172/2161-0959.1000217 · Cited by 1
“Acute renal failure has been classified as recommended by KDIGO [5].”
Background
Does pharmacotherapy improve cardiovascular outcomes in hemodialysis patients?
Mittal, M., Aggarwal, K. B., Littrell, R. L., Agrawal, H., & Alpert, M. (2015) · Hemodialysis International · doi:10.1111/hdi.12352 · Cited by 1
Primary Care of the Solid Organ Transplant Recipient
Wong, C. J. (2020) · Springer eBooks · doi:10.1007/978-3-030-50629-2 · Cited by 19
“Still, despite the weak supporting evidence, it is the recommendation of the KDIGO work group that all post-kidney transplant patients be treated with statin therapy [69].”
Heart Failure in a Patient with End-Stage Kidney Disease on Renal Replacement Therapy
Ahmadmehrabi, S., Rincon-Choles, H., & Tang, W. H. W. (2019) · Springer eBooks · doi:10.1007/978-3-030-21033-5_8
Management of Overt Diabetic Kidney Disease and Uremia
Schernthaner, G., & Prischl, F. C. (2016) · Springer eBooks · doi:10.1007/978-3-319-08873-0_5 · Cited by 1
Progression of Chronic Kidney Disease and Nephroprotective Therapy
Wühl, E., & Schaefer, F. S. (2016) · Springer eBooks · doi:10.1007/978-3-662-52972-0_53 · Cited by 1
Wytyczne PTL/KLRwP/PTK dotyczące postępowania w zaburzeniach lipidowych dla lekarzy rodzinnych 2016
Banach, M., Jankowski, P., Jóźwiak, J., Cybulska, B., Windak, A., Guzik, T., Mamcarz, A., Broncel, M., Tomasik, T., Rysz, J., et al. (2016) · doi:10.5603/kp.2016.0171 · Cited by 1
Documento de información y consenso para la detección y manejo de la enfermedad renal crónica
Maset, R. G., Bover, J., Segura, J., Diezhandino, M. G., del Hoyo, J. C., Martín, J. E. S., Fácila, L., Gamarra, J., García‐Donaire, J. A., Matarin, L. G., et al. (2021) · Nefrología · doi:10.1016/j.nefro.2021.07.010 · Cited by 160
Lipid-lowering agents for the treatment of hyperlipidemia in patients with chronic kidney disease and end-stage renal disease on dialysis: a review
Pryor, J. B., Weber, B. R., Weber, J. V., Lockridge, J. B., & Olyaei, A. J. (2019) · Drugs & Therapy Perspectives · doi:10.1007/s40267-019-00646-4 · Cited by 5
Estimated small dense low-density lipoprotein cholesterol and incident myocardial infarction in patients undergoing dialysis: a nationwide cohort study
Kim, B., Kim, H.-J., Kim, J., Choi, N., & Shin, J.-H. (2026) · Annals medicus · doi:10.1080/07853890.2026.2745096
Injectable Lipid-Lowering Therapies Across the Chronic Kidney Disease Spectrum: Evidence, Safety, and a Stage-Specific Clinical Framework
Baharani, J., & Ramachandran, S. (2026) · Lipidology · doi:10.3390/lipidology3030025
“Treatment decisions in G3b–G5 should therefore be individualised, weighing ASCVD burden, life expectancy and patient goals through shared decision-making [4,24].”
Epidemiology of dyslipidemiia in patients after kidney transplantation (EDYS-AKT 2025): results of a multicenter retrospective cohort study
Kordonova, O. O., Gubarev, K., Voskanyan, S., Svetlakova, D. S., Khayrullin, I. R., Abalyan, A. K., Petizheva, I. A., Shchekaturov, S., Vyunkova, Y. N., Kurakina, Z. I., et al. (2026) · Transplantologiya. The Russian Journal of Transplantation · doi:10.23873/2074-0506-2026-18-3-374-394
The Role of Angiopoietin-Like Proteins 3 and 4 and Their Target Lipases in CKD: A Drug-Target Mendelian Randomization Study
Yang, G., Zhang, D. Y., Fischman, C. J., Cuchel, M., Suszták, K., & Rader, D. J. (2026) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2026.06.015
Parathyroid hormone, pulmonary artery pressure and right ventricular function in patients undergoing/awaiting hemodialysis
Pourkia, R., Saravi, M., Asgharpour, M., Ziaie, N., Akbari, R., Shirafkan, H., & Nabipour, M. (2026) · Caspian Journal of Internal Medicine · doi:10.22088/cjim.17.3.582
“Predialysis patients were defined as GFR less than 30 Ml/Min/1.73m2 (15).”
Dyslipidaemia, Chronic Kidney Disease and Diabetes Mellitus: A Triple Threat to Cardiovascular Health
Forrest, A. S., Majety, P., Mayer, S., & Ganda, O. P. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71180
Beyond LDL-C: Modern Lipid Management for ASCVD Prevention in Primary Care
Carlson, A. M., Zayyad, Z. A., Driesenga, S., Boxley, P., Mishra, A., Uraizee, O., Ephrem, R., Zhang, R., Natsheh, Z., & Shroff, A. R. (2026) · Cardiology and Therapy · doi:10.1007/s40119-026-00473-5
“Given this data, in dialysis-dependent adults, recommendations are to continue but not initiate statin therapy [75].”
Influential
Late-Onset Hypogonadism in Male Hemodialysis Patients: Association with Statin Therapy and Cholesterol Levels.
Fujinami, H., Ando, T., Shibahara, N., Fujita, Y., & Shin, T. (2026) · Journal of Nippon Medical School = Nippon Ika Daigaku zasshi · doi:10.1272/jnms.jnms.2026_93-407
Injectable Lipid-Lowering Therapies in Advanced Chronic Kidney Disease: Efficacy, Safety and the Dialysis Paradox
Damianaki, A., Stambolliu, E., Iliakis, P., Theofilis, P., Vakka, A., Kalliakouda, E., Patsalis, P., Konstantinidis, D., & Petras, D. I. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-026-07934-y
The Chronic Kidney Disease Care Model: Quantifying Management Strategies for Improving Patient Outcomes in the USA
Briggs, A. H., Kohli-Lynch, C., Levy, A. R., Lin, Z.-Y., Chatterjee, S., Donato, B., & Kovesdy, C. (2026) · PharmacoEconomics - Open · doi:10.1007/s41669-026-00649-8
“For CVD treatment optimization, statin therapy was provided to all individuals [47, 48], one BP medication was provided to all untreated hypertensive patients, and one BP medication was added to those with hypertension who are currently uncontrolled (SBP ≥ 140 mmHg or DBP ≥ 90 mmHg) on treatment.”
Joint British Transplantation Society and British Cardiovascular Society guidelines on medical management of coronary artery disease in patients with chronic kidney disease being considered for a kidney transplant.
Asgari, E., Corr, M., Ferro, C., Fossati, N., Graham-Brown, M., Howse, M., Jeetley, P., Jones, G., Kelly, D., Kojro, A., et al. (2026) · Transplantation reviews · doi:10.1016/j.trre.2026.101048
The benefit of LDL-C levels below 55 mg/dL in ESKD patients under statin treatment: A target trial emulation study.
Yen, C., Fan, P.-C., Chen, J.-J., Lee, C.-C., Ho, W.-Y., Tu, Y.-R., Chu, P.-H., Hsiao, C.-C., Hsu, H.-H., & Chang, C.-H. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.121883
Pleiotropic Properties of Statins in Renal Protection Among Patients with Chronic Kidney Disease: A Review of Current Clinical Evidence
Brzeźniak, M., Fitz, E., Daniek, J., Kręcina, F., Kaczmarek, W., Gil, K., Drelich, K., Karbowniczek, A., Mokracka, J., & Grabarczyk, A. (2026) · Quality in Sport · doi:10.12775/qs.2026.64.73697
“[17] • Dose-Dependency: Higher dosing regimens (e.g., 80 mg/day) and the use of high-potency statins are associated with a stronger signal for both muscle and renal toxicity.”
Pentoxifylline and cardiorenal outcomes in advanced CKD with untreated dyslipidemia: a longitudinal cohort study.
Lin, Y.-C., Lai, T.-S., Chou, Y.-H., Lin, S.-L., Huang, J.-W., & Tu, Y.-K. (2026) · Renal Failure · doi:10.1080/0886022x.2026.2694246
Lipid-lowering for people with chronic kidney disease: a narrative review
Tunnicliffe, D. J., Krishnasamy, R., & Strippoli, G. F. (2026) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2024.000059
Kardiovaskuläre Erkrankungen bei chronischer Nierenerkrankung
Gerdes, C., & Busch, M. (2026) · Nephrologie aktuell · doi:10.1055/a-2827-5317
Inclisiran in advanced chronic kidney disease (stage G4–G5 non-dialysis): sustained LDL-C reduction and favorable safety profile at 1-year follow-up in a real-world case series
Nanwani, A. C., Merino, J. C. D. L. F., Mayor, E. J., García, J. D. D., Tudero, C. R., Navarro, A. V., Berrio, E. M., García, A. P., & Vaquero, J. H. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1881641
“These pathophysiological mechanisms accelerate atherosclerosis and substantially increase the incidence of major adverse cardiovascular events (MACE), particularly in patients with CKD stages 4 and 5 (3).”
Influential
Association of remnant cholesterol with long-term outcomes in kidney transplant recipients: a retrospective cohort study
Chen, J., Gao, X., Meng, X., Lou, X., & Chen, J. (2026) · Lipids in Health and Disease · doi:10.1186/s12944-026-02996-1
“Given that Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend statins for most recipients [47], the lack of adjustment for lipid-lowering therapy represents an important limitation.”
Impact of Statin Therapy on Mortality and Cardiovascular Outcomes in End-Stage Renal Disease: A Systematic Review and Meta-Analysis.
Mohammed, A. S., Takagi, M., Yasmeen, U., Desai, R., Ramaiyah, S., Vasudeva, R., Parmar, G. M., & Gupta, K. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001306
Chronic Kidney Disease and Its Role in Cardiovascular Disease.
Swamynathan, R., Dolan, L., Frishman, W., & Aronow, W. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001309
Association of LDLR rs688 Polymorphism With Dyslipidemia in End-Stage Renal Disease: A Case-Control Study
Johnsi Priya, J., Nusrath, A., P., R., S., S. B., & S, I. (2026) · Cureus · doi:10.7759/cureus.108090
Temporal Trends in the Complexity of Nephrology Inpatients: A Population-Based Cohort Study.
Ghimire, A., Wiebe, N., Hemmelgarn, B. R., Manns, B., & Tonelli, M. (2026) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2026.03.042
Self-citation
Cardiometabolic risk burden and kidney function in middle-aged and older adults: evidence from two national, cross-sectional studies in China and the United States
Jiang, W., Zhang, F., Zhang, X., Zhong, Y., & Chen, Y. (2026) · Renal Failure · doi:10.1080/0886022x.2026.2646035
Association between statin therapy as primary prevention and mortality in adults 50 years and older with chronic kidney disease without other indications
Malmquist, J., Davidge, J., Bjurström, K., Halling, A., & Agvall, B. (2026) · Scandinavian Journal of Primary Health Care · doi:10.1080/02813432.2026.2636586
“…data from the UK Biobank, have shown that combining eGFR with albuminuria improves cardiovascular risk prediction compared to traditional models [24]. these findings support the integration of renal function and albuminuria into routine cardiovascular risk assessments in primary care [5,9,24].”
Influential
Guideline-directed medical therapy in Polish patients with chronic coronary syndrome and advanced chronic kidney disease: insights from the ISCHEMIA-CKD trial
Pracoń, R., Anthopolos, R., Lu, Y., Demkow, M., Mazurek, T., Drożdż, J., Pruszczyk, P., Roik, M., Kryczka, K., Henzel, J., et al. (2026) · Postepy w kardiologii interwencyjnej = Advances in interventional cardiology · doi:10.5114/aic.2026.160027
“…clinical trials of statin therapy in patients on dialysis (AURORA and 4D), KDIGO clinical practice guidelines advised against initiating statin therapy in this population of patients but recommended that statins be continued in patients already on such treatment at dialysis initiation [7–9].”
Nephrotic syndrome: Management of dyslipidemia, pathophysiological insights, and therapeutic perspectives
Cherska, M., Pavlenko, O., Zlatkina, V. V., Kuts, L., Taraniuk, K., Деміхов, О., Storozhenko, T. Y., Koleva-Tyutyundzhieva, D. I., Kukharchuk, K., Gohary, A. E., et al. (2026) · Ukrainian Journal of Nephrology and Dialysis · doi:10.31450/ukrjnd.1(89).2026.07

Authors: Wanner, C., the Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members, & Tonelli, M.
Affiliations: University of Würzburg (DE)
University of Alberta (CA)
Corresponding author: Wanner, Christoph
ORCID: Wanner, Christoph
Tonelli, Marcello
Venue: Kidney International
Publisher: Elsevier BV
Published: 2014-06
Volume: 85
Issue: 6
Pages: 1303-1309
ISSN: 0085-2538 (ISSN-L)
DOI: 10.1038/ki.2014.31
OpenAlex: W1978239396
Cited by: 649
References: 0
Citations by year: 2026: 41 · 2025: 65 · 2024: 65 · 2023: 77 · 2022: 68 · 2021: 61 · 2020: 58 · 2019: 57 · 2018: 41 · 2017: 35 · 2016: 33 · 2015: 31 · 2014: 15
FWCI: 37.66
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Kidney International (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
Keywords: lipid control, chronic kidney disease, statins, ezetimibe, LDL cholesterol targets, statin dose escalation, hemodialysis, estimated glomerular filtration rate, cardiovascular risk reduction
MeSH terms: Adolescent, Adult, Age Factors, Hypolipidemic Agents, Child, Renal Dialysis, Humans, Lipids, Middle Aged, Nephrology, Risk Factors, Biomarkers, Treatment Outcome, Evidence-Based Medicine, Dyslipidemias, Renal Insufficiency, Chronic, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Metadata

Record

About these checks